Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1503-1505

  Bobin Dubigeon, Christine ^a,b,c   Jaffré, Isabelle ^a   Joalland, Marie Pierre ^a,c   Classe, Jean Marc ^a   Campone, Mario ^a,d   Hervé, Maxime ^e   Bard, Jean Marie ^a,b,c  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Groupe Métabolisme   (France)

^d Groupe Cytokines et Récepteurs   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Breast cancer; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; PARAOXON; PHENYLACETIC ACID;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATIONAL STUDY; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; ARYLDIALKYLPHOSPHATASE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ENZYME ASSAYS; FEMALE; HUMANS; HYDROLYSIS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PARAOXON; PHENYLACETATES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868301857     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.05.021     Document Type: Article

References (10)

1. Khersonsky O., Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44:6371-6382.
2. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991, 286:152-154.
3. Elkiran E.T., Mar N., Aygen B., Gursu F., Karaoglu A., Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007, 7:48.
4. Krzystek-Korpacka M., Boehm D., Matusiewicz M., Diakowska D., Grabowski K., Gamian A. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes - connection with inflammation. Clin Biochem 2008, 41:804-811.
5. Stevens V.L., Rodriguez C., Talbot J.T., Pavluck A.L., Thun M.J., Calle E.E. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort. Prostate 2008, 68:1336-1340.
6. Kitchen B.J., Masters C.J., Winzor D.J. Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase. Biochem J 1973, 135:93-99.
7. Liu C., Liu L. Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis. Tumour Biol 2011, 32:1233-1240.
8. Saadat M. Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis. Cancer Epidemiol 2012, 36:e101-e103. 10.1016/j.canep.2011.10.015.
9. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35:1126-1138.
10. Camps J., Marsillach J., Joven J. Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. Mini Rev Med Chem 2009, 9:911-920.